Richiedi info sul prodotto
Estimated delivery: 1-3 business days
Information on returns and shipments
Payment methods
Medicated plasters based on dicloflenac sodium; useful for muscle pain
For short-term treatments. Local symptomatic relief of pain associated with acute muscle strains, sprains or bruises of the limbs following non-penetrating trauma.
Each medicated plaster contains 140 mg of diclofenac sodium.
Excipients with known effect: 2.8 mg of butylhydroxytoluene (E321) and 1400 mg of propylene glycol (E1520) per plaster.
glycerol propylene glycol (E1520) diisopropyl adipate sorbitol liquid (crystallizing) (E420) carmellose sodium polyacrylic acid sodium salt basic butylated copolymer methacrylate edetate disodium sodium sulfite (E221) butylhydroxytoluene (E321) aluminium-potassium bis(sulfate) colloidal anhydrous silica light kaolin (natural) macrogol lauryl ether (9 EO units) levomenthol tartaric acid purified water non-woven polyester backing polypropylene protective sheet
In adults, apply one medicated plaster twice a day, in the morning and in the evening, to the painful area. The maximum daily dose is 2 medicated plasters, even if more than one area is to be treated. Only one painful area should be treated at a time. The diclofenac medicated plaster should be used for as long as possible. as soon as possible in relation to the indication for use.
Paediatric population Children and adolescents under 16 years: The use of this medicated plaster is not recommended in children and adolescents under 16 years of age because there are insufficient data to evaluate the safety and efficacy of the medicinal product.
For cutaneous use only. The product should be applied only to intact, healthy skin and should not be held in place while bathing or showering. Cut the pouch containing the medicated plaster as directed. Take out a medicated plaster, remove the plastic film used to protect the adhesive surface and apply the plaster to the painful joint or surface. If necessary, the medicated plaster can be held in place using an elastic band. Carefully reseal the pouch with a sliding seal. The patch must be used whole.
Based on the limited data available, short-term treatments are recommended. The therapeutic benefit of administrations lasting more than 7 days has not been established. If no improvement is seen following the recommended treatment period, a doctor should be consulted (see section 4.4). In adults and adolescents over 16 years of age, if use of the product for longer periods is necessary, the patient should be advised to consult a doctor. If the pain is relieved within 7 days or if symptoms worsen, patients or parents of the adolescent are advised to consult their doctor.
If diclofenac medicated plasters are used on large areas of skin and for a prolonged period of time, the possibility of systemic adverse events cannot be excluded (see the Summary of Product Characteristics of the systemic formulations of diclofenac).
Although systemic effects are expected to be minimal, Diclofenac Teva should be used with caution in patients with impaired renal, cardiac or hepatic function, or with a history of peptic ulcer or inflammatory bowel disease or haemorrhagic diathesis.
Non-steroidal anti-inflammatory drugs ..., or haemorrhagic diathesis.
Non-steroidal anti-inflammatory drugs should be used with caution in patients with impaired renal, cardiac or hepatic function, or with a history of peptic ulcer or inflammatory bowel disease, or haemorrhagic diathesis.
Non-steroidal anti-inflammatory drugs should be used with caution in patients with impaired renal, cardiac or hepatic function, or with a history of peptic ulcer or inflammatory bowel disease, or ha Elderly patients, as they are more susceptible to side effects. The medicated plaster should be applied only to intact, healthy skin and should not be applied to broken skin or open wounds.
Diclofenac Teva should not come into contact with or be applied to the eyes or mucous membranes. The medicated plaster should not be used with an occlusive dressing that does not allow air to pass through. Do not administer together with other medicinal products containing diclofenac or other NSAIDs, whether topically or systemically.
Patients should be advised to avoid direct exposure of the treated areas to sunlight or sunlamps for approximately one day after removing the medicated plaster to reduce the risk of photosensitivity. If symptoms persist for more than one day, the medicated plaster should be removed immediately. If symptoms persist for more than 3 days, or worsen, you should contact your doctor.
Undesirable effects can be minimized by using the lowest effective dose for the shortest duration necessary to control symptoms.
Bronchospasm may occur in patients who suffer or have suffered in the past from bronchial asthma or allergies. If a skin rash develops after applying Diclofenac Teva, treatment should be stopped immediately.
Diclofenac Teva contains propylene glycol and butylhydroxytoluene. Propylene glycol may cause skin irritation. Butylhydroxytoluene may cause skin irritation. cause localized skin reactions (e.g. contact dermatitis) or irritation to the eyes and mucous membranes.
If Diclofenac Teva is used correctly, the rate of systemic exposure is low, and therefore the interactions reported following the use of oral diclofenac are unlikely to occur.
No cases of overdose have been reported. In case of serious systemic side effects following incorrect use of the drug or accidental overdose (e.g. in children), appropriate therapeutic measures used for intoxication with nonsteroidal anti-inflammatory drugs must be applied.
Fertility: the use of diclofenac may impair female fertility and is not recommended in women attempting to become pregnant. Diclofenac should be discontinued in women who have difficulties conceiving or who are undergoing investigation of fertility.
Pregnancy: Available clinical data regarding the cutaneous use of diclofenac during pregnancy are insufficient. Animal studies have shown reproductive toxicity after systemic application. The systemic concentration of diclofenac, compared to oral formulations, is lower after topical administration.
Based on experience with treatment with systemically administered NSAIDs, the following is recommended: Inhibition of prostaglandin synthesis may adversely affect pregnancy and/or embryo/fetal development. Results of epidemiological studies suggest an increased risk of miscarriage and of cardiac malformation and gastroschisis after use of a prostaglandin synthesis inhibitor in early pregnancy. The absolute risk of cardiac malformations increased from less than 1% to approximately 1.5%. The risk is believed to increase with dose and duration of therapy. In animals, administration of prostaglandin synthesis inhibitors has been shown to result in increased pre- and post-implantation loss and embryo-fetal mortality. Additionally, an increased incidence of various malformations, including cardiovascular, has been reported in animals administered prostaglandin synthesis inhibitors during the organogenetic period. During the first and second trimesters of pregnancy, diclofenac should not be administered unless clearly necessary.
If diclofenac is used by a woman attempting to conceive, or during the first and second trimesters of pregnancy, the dose should be kept as low as possible and the duration of treatment as short as possible. The maximum daily dose is two medicated plasters. During the third trimester of pregnancy, all prostaglandin synthesis inhibitors may expose the fetus to: - cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); - renal dysfunction that may progress to renal failure with oligohydramnios; the mother and the newborn at the end of pregnancy to: - possible prolongation of bleeding time, an antiaggregant effect that may occur even at very low doses; - inhibition of uterine contractions resulting in delayed or prolonged labor.
Consequently, the use of diclofenac is contraindicated during the third trimester of pregnancy.
Breastfeeding: Minimal quantities of diclofenac and its metabolites are excreted in breast milk. However, at therapeutic doses of diclofenac medicated plasters, no effects on the nursing infant are anticipated. Due to the lack of controlled studies in breastfeeding women, the product should be used during breastfeeding only under the advice of a healthcare professional. In this circumstance, diclofenac medicated plasters should not be applied to the breasts of nursing mothers, nor elsewhere on large areas of skin or for a prolonged period of time.
10 medicated plasters
This product has been on sale since 08/03/2022
In the last 30 days, the product's lowest price was 15,15 €
Ottimo prodotto per i dolori lombari
Estimated delivery: 1-3 business days
Estimated delivery: 1-3 business days
Estimated delivery: 1-3 business days
Estimated delivery: 1-3 business days
